Blood Banks Charged ₹ 147 Cr From Patients In Six Years In Mumbai, Says RTI

Mumbai : Complaints were made to the State Blood Transfusion Council that blood banks were charging extra fees from patients and their relatives for providing blood and its components. Taking cognizance of these complaints, the State Blood Transfusion Council had decided in 2020 to levy a fine of five times more than the fee charged by the concerned blood banks. But earlier, the State Blood Transfusion Council and the Food and Drug Administration had tightened their belts to impose fines on looting by blood banks. Accordingly, only 20 percent of the additional fee was directed to be deposited with the council. Accordingly, when the council announced the penalty amount, the blood banks objected to it. Therefore, the council appointed an accounting firm to audit the accounts. According to the information provided by this company, it was revealed that 22 private blood banks in Mumbai collected INR 147 crore from additional charges. State Blood Transfusion Council provided this information to activist Chetan Kothari through Right to Information.

Kokilaben Dhirubhai Ambani Hospital in Andheri collected the highest additional charges of 3 crore 4 lakh 18 thousand 965 rupees. Under that, Hinduja Hospital in Mahim has collected 2 crore 32 lakh 45 thousand 640 rupees, Jaslok Hospital has collected 2 crore 26 lakh 75 thousand 850 rupees additional charges. The council has imposed a 20 percent penalty on 22 blood banks in Mumbai for charging extra. Accordingly, an amount of ₹ 27.63 crore has been levied as penalty. This fine amount has been recovered from these blood banks.

According to the decision taken by the State Blood Transfusion Council in 2020, a fine of five times the additional fee charged by blood banks will be levied. From that, the amount will be returned to the patients and the remaining amount will be deposited with the Council. However, there is no provision to refund any amount to the patient from the penalty on additional charges during the period 2014 to 2019.

Related Posts

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

New Delhi: Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP in…

STF busts fake meds racket spread across 6 states

Dehradun: Uttarakhand special task force (STF) on Friday busted an online fake medicine racket operating through a Facebook page that allegedly sold counterfeit drugs, including cancer medicines, at discounts of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states

All the Way from Teeth to Tee: Hole in One

All the Way from Teeth to Tee: Hole in One

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug